DZ-2384

CAT: 0804-HY-120120Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-120120Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
DZ-2384 is a potent microtubule-targeting agent. DZ-2384 increases the rescue frequency and preserves the microtubule network in nonmitotic cells and primary neurons. DZ-2384 acts synergistically with anti-CTLA-4 immunotherapy in Taxane-sensitive and Taxane-resistant xenograft murine models of triple-negative breast cancer (TNBC) . DZ-2384 exhibits potent antitumor activity in adult acute lymphocytic leukemia (ALL) models. DZ-2384 can be used for cancer research, such as TNBC and ALL[1][2].
CAS Number
[1403850-91-8]
UNSPSC
12352005
Target
Microtubule/Tubulin
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
FC1=CC=C2C([C@@]34C5=C(C6=NC(CO)=CO6)N=C([C@@H](NC([C@@H](NC([C@@H](O)C(C)C)=O)CC7=CC=C(O[C@@]4([H])N2)C3=C7)=O)C(C)(C)C)O5)=C1
Molecular Formula
C34H36FN5O7
Molecular Weight
645.68
References & Citations
[1]Wieczorek M, et al. The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity. Sci Transl Med. 2016 Nov 16;8 (365) :365ra159.|[2]Bernier C, et al. DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. Anticancer Drugs. 2018 Sep;29 (8) :774-785.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products